Intellia Therapeutics, Inc. (NTLA) News
Follow Intellia Therapeutics, Inc. (NTLA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Anthropic AI Discovery Gene-Editing Stocks Falling
Gene-editing stocks fell Wednesday after Anthropic's Claude AI model identified an enzyme system with characteristics similar to technology used to alter DNA.Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia
NEWS | Sep 24, 2026, 12:51 PM UTC
L
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
Gene-editing stocks sold off on Wednesday after Anthropic said its Claude model had flagged a phage enzyme system that shares a few design traits with CRISPR — the platform behind approved and experimental DNA-editing me
EQUITY | Sep 23, 2026, 09:49 PM UTC
L
Cathie Wood Makes Striking Switch Between AI Stock Giants
Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms NASDAQ:META while selling a nearly identical dollar amount of Alphabet NAS
EQUITY | Sep 15, 2026, 12:21 PM UTC
L
NTLA: Late-stage gene editing therapies for HAE and TTR advance, with FDA review and strong market prospects
The company is advancing in vivo gene editing with late-stage programs for HAE and TTR, expecting FDA approval for its HAE therapy by March 10. Strong efficacy and safety data support broad market potential, with a targe
REGULATION | Sep 14, 2026, 10:01 PM UTC
L
NTLA: Late-stage gene editing therapies for HAE and TTR advance, with FDA review and targeted launch plans
The company is advancing late-stage in vivo gene editing therapies for HAE and TTR, with FDA review for HAE underway and a targeted commercial strategy in place. Strong clinical data, robust financial planning, and strat
REGULATION | Sep 14, 2026, 09:13 PM UTC
L
Citizens maintains $30 price target on Intellia Therapeutics
Citizens maintained its $30.00/share price target for Intellia Therapeutics.
EQUITY | Sep 09, 2026, 01:14 PM UTC
L
Wedbush maintains Intellia Therapeutics at neutral
Wedbush maintained its neutral rating on Intellia Therapeutics.
EQUITY | Sep 09, 2026, 12:28 PM UTC
L
HC Wainwright maintains Intellia Therapeutics $25 price target
HC Wainwright & Co. maintained its $25.00 per share price target for Intellia Therapeutics, according to Benzinga’s ratings actions.
EQUITY | Sep 09, 2026, 10:44 AM UTC
M
Intellia says FDA accepted BLA for lonvo-z
Intellia said the FDA accepted the BLA for lonvo-z, granted Priority Review and set a PDUFA action date of March 10, 2027.
REGULATION | Sep 08, 2026, 08:15 PM UTC
M
FDA grants priority review for Intellia rare genetic disease therapy
Intellia Therapeutics’ experimental gene-editing treatment for a rare genetic disease has received U.S. FDA priority review status, putting the stock back in focus among investors.
REGULATION | Sep 08, 2026, 02:09 PM UTC
M
FDA accepts Intellia biologics license application for priority review
Intellia Therapeutics said the U.S. FDA has accepted its biologics license application for lonvoguran ziclumeran (Lonvo-z) for hereditary angioedema (HAE) and granted priority review.
REGULATION | Sep 08, 2026, 12:07 PM UTC
M
Intellia (NTLA) FDA accepts Lonvo-z BLA for hereditary angioedema
Intellia Therapeutics said the FDA accepted its biologics license application for Lonvoguran ziclumeran (Lonvo-z) for hereditary angioedema and granted priority review.
REGULATION | Sep 08, 2026, 12:00 PM UTC
L
Intellia awards inducement grants under Nasdaq Rule 5635(c)(4)
Intellia Therapeutics said it awarded inducement grants on September 1, 2026 under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:07 PM UTC
L
NTLA reports inducement grants under Nasdaq Rule 5635(c)(4)
Intellia Therapeutics reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:05 PM UTC
M
Intellia Therapeutics lands non-dilutive OrbiMed debt facility up to $400M
Intellia Therapeutics secured a non-dilutive debt facility with OrbiMed for up to $400 million: $75 million funded upfront and $325 million tied to milestones, aimed at added strategic flexibility.
EQUITY | Sep 04, 2026, 12:57 PM UTC
M
NTLA secures non-dilutive debt facility with OrbiMed up to $400 million
NTLA said it secured a non-dilutive debt facility with OrbiMed for up to $400 million.
EQUITY | Sep 04, 2026, 12:50 PM UTC
L
Intellia Therapeutics to present at Morgan Stanley Global Healthcare conference
Intellia Therapeutics said it will present at the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Sep 04, 2026, 12:07 PM UTC
L
NTLA - Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
NTLA - Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
EQUITY | Sep 04, 2026, 12:00 PM UTC
L
NTLA - Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
NTLA - Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
EARNINGS | Aug 06, 2026, 11:00 AM UTC
L
NTLA - Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates - Cli
NTLA - Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
EARNINGS | Jul 30, 2026, 12:00 PM UTC
L
NTLA Downgrade from Peerperform to Underperform W/$9.00 PT at Wolfe Research
NTLA Downgrade from Peerperform to Underperform W/$9.00 PT at Wolfe Research
EQUITY | Jul 16, 2026, 11:54 AM UTC
L
NTLA downgraded from Peer Perform to Underperform W/ $9 PT @ Wolfe
NTLA downgraded from Peer Perform to Underperform W/ $9 PT @ Wolfe
EQUITY | Jul 16, 2026, 11:23 AM UTC